AGIOS PHARMACEUTICALS, INC. Insider Trading for February 2021
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in AGIOS PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in AGIOS PHARMACEUTICALS, INC. for February 2021.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 24 2021 | AGIO | AGIOS PHARMACEUTIC ... | Schenkein David P | Director | Option Exercise | M | 0.00 | 2,774 | 0 | 2,775 | |
Feb 24 2021 | AGIO | AGIOS PHARMACEUTIC ... | Schenkein David P | Director | Payment of Exercise | F | 0.00 | 821 | 0 | 112,591 | 113.4 K to 112.6 K (-0.72 %) |
Feb 24 2021 | AGIO | AGIOS PHARMACEUTIC ... | Schenkein David P | Director | Buy | M | 0.00 | 2,774 | 0 | 113,412 | 110.6 K to 113.4 K (+2.51 %) |
Feb 24 2021 | AGIO | AGIOS PHARMACEUTIC ... | Alenson Carman | Principal Accountin ... | Option Exercise | M | 0.00 | 692 | 0 | 691 | |
Feb 24 2021 | AGIO | AGIOS PHARMACEUTIC ... | Alenson Carman | Principal Accountin ... | Payment of Exercise | F | 0.00 | 199 | 0 | 1,795 | 2 K to 1.8 K (-9.98 %) |
Feb 24 2021 | AGIO | AGIOS PHARMACEUTIC ... | Alenson Carman | Principal Accountin ... | Buy | M | 0.00 | 692 | 0 | 1,994 | 1.3 K to 2 K (+53.15 %) |
Feb 24 2021 | AGIO | AGIOS PHARMACEUTIC ... | Bowden Christopher | Chief Medical Offic ... | Option Exercise | M | 0.00 | 3,334 | 0 | 3,333 | |
Feb 24 2021 | AGIO | AGIOS PHARMACEUTIC ... | Bowden Christopher | Chief Medical Offic ... | Payment of Exercise | F | 0.00 | 986 | 0 | 15,410 | 16.4 K to 15.4 K (-6.01 %) |
Feb 24 2021 | AGIO | AGIOS PHARMACEUTIC ... | Bowden Christopher | Chief Medical Offic ... | Buy | M | 0.00 | 3,334 | 0 | 16,396 | 13.1 K to 16.4 K (+25.52 %) |
Feb 17 2021 | AGIO | AGIOS PHARMACEUTIC ... | Bowden Christopher | Chief Medical Offic ... | Option Exercise | M | 0.00 | 2,750 | 0 | 0 | |
Feb 17 2021 | AGIO | AGIOS PHARMACEUTIC ... | Bowden Christopher | Chief Medical Offic ... | Option Exercise | M | 0.00 | 4,000 | 0 | 8,000 | |
Feb 17 2021 | AGIO | AGIOS PHARMACEUTIC ... | Bowden Christopher | Chief Medical Offic ... | Payment of Exercise | F | 0.00 | 2,069 | 0 | 13,062 | 15.1 K to 13.1 K (-13.67 %) |
Feb 17 2021 | AGIO | AGIOS PHARMACEUTIC ... | Bowden Christopher | Chief Medical Offic ... | Buy | M | 0.00 | 2,750 | 0 | 15,131 | 12.4 K to 15.1 K (+22.21 %) |
Feb 17 2021 | AGIO | AGIOS PHARMACEUTIC ... | Bowden Christopher | Chief Medical Offic ... | Buy | M | 0.00 | 4,000 | 0 | 12,381 | 8.4 K to 12.4 K (+47.73 %) |
Feb 17 2021 | AGIO | AGIOS PHARMACEUTIC ... | FOUSE JACQUALYN A | Chief Executive Off ... | Option Exercise | M | 0.00 | 11,333 | 0 | 22,667 | |
Feb 17 2021 | AGIO | AGIOS PHARMACEUTIC ... | FOUSE JACQUALYN A | Chief Executive Off ... | Payment of Exercise | F | 0.00 | 3,398 | 0 | 58,363 | 61.8 K to 58.4 K (-5.50 %) |
Feb 17 2021 | AGIO | AGIOS PHARMACEUTIC ... | FOUSE JACQUALYN A | Chief Executive Off ... | Buy | M | 0.00 | 11,333 | 0 | 61,761 | 50.4 K to 61.8 K (+22.47 %) |
Feb 17 2021 | AGIO | AGIOS PHARMACEUTIC ... | Alenson Carman | Principal Accountin ... | Option Exercise | M | 0.00 | 790 | 0 | 0 | |
Feb 17 2021 | AGIO | AGIOS PHARMACEUTIC ... | Alenson Carman | Principal Accountin ... | Option Exercise | M | 0.00 | 889 | 0 | 1,777 | |
Feb 17 2021 | AGIO | AGIOS PHARMACEUTIC ... | Alenson Carman | Principal Accountin ... | Payment of Exercise | F | 0.00 | 561 | 0 | 1,302 | 1.9 K to 1.3 K (-30.11 %) |
Feb 17 2021 | AGIO | AGIOS PHARMACEUTIC ... | Alenson Carman | Principal Accountin ... | Buy | M | 0.00 | 790 | 0 | 1,863 | 1.1 K to 1.9 K (+73.63 %) |
Feb 17 2021 | AGIO | AGIOS PHARMACEUTIC ... | Alenson Carman | Principal Accountin ... | Buy | M | 0.00 | 889 | 0 | 1,073 | 184 to 1.1 K (+483.15 %) |
Feb 17 2021 | AGIO | AGIOS PHARMACEUTIC ... | Schenkein David P | Director | Option Exercise | M | 0.00 | 8,125 | 0 | 0 | |
Feb 17 2021 | AGIO | AGIOS PHARMACEUTIC ... | Schenkein David P | Director | Payment of Exercise | F | 0.00 | 2,540 | 0 | 110,638 | 113.2 K to 110.6 K (-2.24 %) |
Feb 17 2021 | AGIO | AGIOS PHARMACEUTIC ... | Schenkein David P | Director | Buy | M | 0.00 | 8,125 | 0 | 113,178 | 105.1 K to 113.2 K (+7.73 %) |
Feb 12 2021 | AGIO | AGIOS PHARMACEUTIC ... | Car Bruce | Chief Scientific Of ... | Option Exercise | A | 56.68 | 44,000 | 2,493,920 | 44,000 | |
Feb 12 2021 | AGIO | AGIOS PHARMACEUTIC ... | Car Bruce | Chief Scientific Of ... | Option Exercise | A | 0.00 | 11,000 | 0 | 11,000 | |
Feb 12 2021 | AGIO | AGIOS PHARMACEUTIC ... | Bowden Christopher | Chief Medical Offic ... | Option Exercise | A | 56.68 | 44,000 | 2,493,920 | 44,000 | |
Feb 12 2021 | AGIO | AGIOS PHARMACEUTIC ... | Bowden Christopher | Chief Medical Offic ... | Option Exercise | A | 0.00 | 11,000 | 0 | 11,000 | |
Feb 12 2021 | AGIO | AGIOS PHARMACEUTIC ... | Biller Jonathan | Chief Financial Off ... | Option Exercise | A | 56.68 | 44,000 | 2,493,920 | 44,000 | |
Feb 12 2021 | AGIO | AGIOS PHARMACEUTIC ... | Biller Jonathan | Chief Financial Off ... | Option Exercise | A | 0.00 | 11,000 | 0 | 11,000 | |
Feb 12 2021 | AGIO | AGIOS PHARMACEUTIC ... | Alenson Carman | Principal Accountin ... | Option Exercise | A | 56.68 | 2,961 | 167,829 | 2,961 | |
Feb 12 2021 | AGIO | AGIOS PHARMACEUTIC ... | Alenson Carman | Principal Accountin ... | Option Exercise | A | 0.00 | 5,922 | 0 | 5,922 |